Compare CYN & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 24.3M |
| IPO Year | 2021 | 2012 |
| Metric | CYN | TXMD |
|---|---|---|
| Price | $1.42 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 273.8K | 16.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | $368,138.00 | ★ $1,761,000.00 |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | ★ N/A | $212.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.29 | $0.98 |
| 52 Week High | $41.54 | $2.95 |
| Indicator | CYN | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 50.27 |
| Support Level | $1.33 | $1.93 |
| Resistance Level | $1.76 | $2.10 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 22.02 | 63.64 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.